Literature DB >> 32966936

Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.

Cristina Fortuno1, Tina Pesaran2, Jessica Mester3, Jill Dolinsky2, Amal Yussuf2, Kelly McGoldrick2, Paul A James4, Amanda B Spurdle5.   

Abstract

Pathogenic germline variants in the TP53 gene predispose to a wide range of cancers, known collectively as Li-Fraumeni syndrome (LFS). There has been much research aimed to identify genotype-phenotype correlations, that is, differences between variant location and/or effect and cancer spectrum. These correlations, should they exist, have potential to impact clinical management of carriers. Review of previously published studies showed a variety of study designs and inconsistency in reported findings. Here, we used pooled data from 427 TP53 carriers who had undergone multigene panel testing and 154 TP53 carriers identified by single-gene testing to investigate correlations between TP53 genotype (truncating variants, hotspot variants, other missense variants with dominant-negative effect, missense variants without dominant-negative effect) and a number of LFS-selected malignancies. Our results suggest that carriers of truncating and hotspot variants might be more likely to present with LFS cancers and have shorter time to first cancer diagnosis compared to carriers of other variant types. However, the differences observed were minor, and we conclude that there is currently insufficient evidence to consider location and/or molecular effect of pathogenic variants to assist with clinical management of TP53 carriers. Larger studies are necessary to confirm the correlations suggested by our analysis.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32966936     DOI: 10.1016/j.cancergen.2020.09.002

Source DB:  PubMed          Journal:  Cancer Genet


  5 in total

Review 1.  Melanoma in patients with Li-Fraumeni syndrome (Review).

Authors:  Florica Sandru; Mihai Cristian Dumitrascu; Aida Petca; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

2.  Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.

Authors:  Kelvin César de Andrade; Payal P Khincha; Jessica N Hatton; Megan N Frone; Talia Wegman-Ostrosky; Phuong L Mai; Ana F Best; Sharon A Savage
Journal:  Lancet Oncol       Date:  2021-11-12       Impact factor: 41.316

3.  Revisiting the indication for prophylactic contralateral mastectomy in patients with Li-Fraumeni syndrome and breast cancer. Case report

Authors:  Ximena Briceño-Morales; Clara Briceño-Morales; Silvia Inés Guerrero-Macías; Ana María Pedroza-Durán; Raúl Alexis Súarez-Rodríguez
Journal:  Rev Colomb Obstet Ginecol       Date:  2021-09-30

4.  Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.

Authors:  Judith Penkert; Farina J Strüwe; Christina M Dutzmann; Beate B Doergeloh; Emilie Montellier; Claire Freycon; Myriam Keymling; Heinz-Peter Schlemmer; Birte Sänger; Beatrice Hoffmann; Tanja Gerasimov; Claudia Blattmann; Sebastian Fetscher; Michael Frühwald; Simone Hettmer; Uwe Kordes; Vita Ridola; Sabine Kroiss Benninger; Angela Mastronuzzi; Sarah Schott; Juliane Nees; Aram Prokop; Antje Redlich; Markus G Seidel; Stefanie Zimmermann; Kristian W Pajtler; Stefan M Pfister; Pierre Hainaut; Christian P Kratz
Journal:  J Hematol Oncol       Date:  2022-08-16       Impact factor: 23.168

Review 5.  Li-Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment.

Authors:  Valentina Rocca; Giovanni Blandino; Lucia D'Antona; Rodolfo Iuliano; Silvia Di Agostino
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.